Search results for "antico"

showing 10 items of 736 documents

Evaluation of carbamazepine uptake and metabolization by Typha spp., a plant with potential use in phytotreatment

2011

Abstract Phytoremediation technologies such as constructed wetlands have shown higher efficiencies in removal of pharmaceuticals from wastewaters than conventional wastewater treatment processes, and plants seem to have an important role in the removal of some of those compounds. In this context, a study was conducted to assess tolerance, uptake, and metabolism of the epilepsy drug, carbamazepine, by the macrophyte Typha spp. This evaluation was conducted in hydroponic solutions with 0.5–2.0 mg/L of this pharmaceutical for a maximum period of 21 days. The removal of carbamazepine from nutrient solutions by the plants reached values of 82% of the initial contents. Furthermore, a metabolite (…

Spectrometry Mass Electrospray IonizationEnvironmental EngineeringMetaboliteBioengineeringContext (language use)Typhaceaechemistry.chemical_compoundNutrientTandem Mass SpectrometryBotanymedicineTypha spp.Waste Management and DisposalTyphaPhytotreatmentbiologyConstructed wetlandsRenewable Energy Sustainability and the EnvironmentGeneral MedicineCarbamazepinebiology.organism_classificationPhytoremediationPhytoremediationBiodegradation EnvironmentalCarbamazepinechemistryCatalaseOxidative stressEnvironmental chemistrybiology.proteinPharmaceuticalsAnticonvulsantsWater Pollutants ChemicalChromatography Liquidmedicine.drug
researchProduct

Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated hep…

2003

Item does not contain fulltext OBJECTIVES: The aim of this study was to evaluate percutaneous coronary intervention (PCI) in the Assessment of the Safety and Efficacy of New Thrombolytic Regimens (ASSENT-3) trial. BACKGROUND: In the ASSENT-3 trial, co-therapy with abciximab (ABC) or enoxaparin (ENOX) reduced ischemic complications after ST-elevation acute myocardial infarction treated with tenecteplase when compared with unfractionated heparin (UFH). The effect of these new co-therapies on the results of PCI is unknown. METHODS: Clinical outcomes in patients who received co-therapy with ABC, ENOX, or UFH and subsequently underwent an elective (n = 1,064) or urgent (n = 716) PCI in the ASSEN…

MaleAbciximabmedicine.medical_treatmentMyocardial InfarctionAlbertaBelgiumRecurrenceGermanyAbciximabAngioplasty Balloon CoronaryHeart lung and circulation [UMCN 2.1]Netherlandseducation.field_of_studyAntibodies MonoclonalMiddle AgedTreatment OutcomeItalyElective Surgical ProceduresTissue Plasminogen ActivatorDrug Therapy CombinationFemaleCardiology and Cardiovascular MedicineEnoxaparin sodiummedicine.drugmedicine.medical_specialtymedicine.drug_classPopulationLow molecular weight heparinTenecteplasePlatelet Glycoprotein GPIIb-IIIa ComplexDrug Administration ScheduleImmunoglobulin Fab FragmentsFibrinolytic AgentsInternal medicineNorth CarolinamedicineHumansEnoxaparineducationEmergency TreatmentSwedenHeparinbusiness.industryAnticoagulantsPercutaneous coronary interventionSurvival AnalysisSurgerySpainConventional PCITenecteplasebusinessFibrinolytic agentJournal of the American College of Cardiology
researchProduct

Atrial fibrillation in high-risk patients with ischaemic stroke – Authors' reply

2017

medicine.medical_specialtyHigh risk patientsbusiness.industryMEDLINEAnticoagulantsAtrial fibrillation030204 cardiovascular system & hematologymedicine.diseaseStroke03 medical and health sciences0302 clinical medicineText miningRisk FactorsInternal medicineAtrial FibrillationIschaemic strokeCardiologyHumansMedicineNeurology (clinical)businessStroke030217 neurology & neurosurgeryThe Lancet Neurology
researchProduct

Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II)

2010

SummaryThis trial compared the efficacy and safety of oral dabigatran, a direct thrombin inhibitor, versus subcutaneous enoxaparin for extended thromboprophylaxis in patients undergoing total hip arthroplasty. A total of 2,055 patients were randomised to 28–35 days treatment with oral dabigatran, 220 mg once-daily, starting with a half-dose 1–4 hours after surgery, or subcutaneous enoxaparin 40 mg once-daily, starting the evening before surgery. The primary efficacy outcome was a composite of total venous thromboembolism [VTE] (venographic or symptomatic) and death from all-causes. The main secondary composite outcome was major VTE (proximal deep-vein thrombosis or non-fatal pulmonary embol…

Malemedicine.medical_specialtymedicine.drug_classArthroplasty Replacement HipInjections SubcutaneousAdministration OralLow molecular weight heparinHemorrhage030226 pharmacology & pharmacyAntithrombinsDabigatranlaw.invention03 medical and health sciencesPostoperative Complicationsoral thromboprophylaxis dabigatran flebography0302 clinical medicineDouble-Blind MethodRandomized controlled triallawHumansMedicineEnoxaparinAgedVenous Thrombosisbusiness.industryAnticoagulantAnticoagulantsVenous ThromboembolismHematologyMiddle Agedmedicine.diseaseSurvival AnalysisDabigatranSurgeryPulmonary embolismVenous thrombosisDirect thrombin inhibitorAnesthesiabeta-AlanineBenzimidazolesFemalebusinessEnoxaparin sodiummedicine.drugThrombosis and Haemostasis
researchProduct

N-valproyl-L-tryptophan for CNS-targeting: synthesis, characterization and efficacy in vitro studies of a new potential antiepileptic drug.

2010

A new aminoacidic derivative of valproic acid (VPA) has been synthesized and characterized by analytical and spectral data. The rationale for the preparation of such potential antiepileptic agent is based on the observation that chemical combination of the anticonvulsant pharmacophore, VPA with essential aminoacids could afford more effective and less toxic actives. The synthesis, characterization, physico-chemical parameters functional for crossing Blood Brain Barrier of N-valproyl-L-tryptophan (4) are reported. The Log D pH7.4 (0.3) indicates that (4) is adequate to cross biological membranes. Its chemical and enzymatic stability were assessed. The experiments indicate high stability of c…

Malemedicine.medical_treatmentHippocampal formationPharmacologyIn Vitro TechniquesBlood–brain barrierSettore BIO/09 - FisiologiaHippocampuschemistry.chemical_compoundDrug StabilityIn vivoDrug DiscoverymedicineAnimalsRats WistarValproic AcidEpilepsyDipeptidesAminoacidic derivative Antiepileptic Drug CNS-Targeting Enzymatic Stability Seizure Like Events Model Valproic acidIn vitroElectrophysiological PhenomenaRatsmedicine.anatomical_structureAnticonvulsantchemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoAnticonvulsantsPharmacophoreDerivative (chemistry)medicine.drugMedicinal chemistry (Shariqah (United Arab Emirates))
researchProduct

Variables affecting the quality of anticoagulation in atrial fibrillation patients newly initiating vitamin K antagonists: insights from the national…

2021

Abstract Aims Vitamin K antagonists (VKAs) are effective drugs reducing the risk for stroke in atrial fibrillation (AF), but the benefits derived from such therapy depend on the international normalized ratio (INR) maintenance in a narrow therapeutic range. Here, we aimed to determine independent variables driving poor anticoagulation control [defined as a time in therapeutic range (TTR) <65%] in a ‘real world’ national cohort of AF patients. Methods and results The SULTAN registry is a multicentre, prospective study, involving patients with non-valvular AF from 72 cardiology units expert in AF in Spain. At inclusion, all patients naïve for oral anticoagulation were started with VKAs…

Malemedicine.medical_specialtyVitamin K030204 cardiovascular system & hematologyAmiodaroneCoronary artery disease03 medical and health sciences0302 clinical medicinePhysiology (medical)Internal medicineAtrial FibrillationHumansMedicineInternational Normalized RatioProspective StudiesRegistries030212 general & internal medicineProspective cohort studyStrokeAgedAged 80 and overbusiness.industryProportional hazards modelAnticoagulantsAtrial fibrillationOdds ratioMiddle Agedmedicine.diseaseConfidence intervalStrokeFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugEP Europace
researchProduct

Ischemic stroke risk during long-term follow up in patients with successful catheter ablation for atrial fibrillation in Korea

2018

The interruption of oral anticoagulation therapy (OAC) after CA of atrial fibrillation (AF) is controversial. The purpose of this study was to evaluate the relationship between successful long-term outcomes of catheter resection and SR maintenance and ischemic stroke risk in Korea. We studied 1,548 consecutive patients who were followed up for more than 2 years after CA of AF. We investigated the incidence of ischemic stroke during long-term follow-up. Compared to the AF recurrence group (n = 619), the sinus rhythm (SR) maintenance group (n = 929) had more paroxysmal AF (74.6% versus 44.4%, p<0.001), smaller LA size (39.9±5.7mm versus 42.3±6.0mm, p<0.001), and younger age (54.2±10.9 years v…

Malemedicine.medical_treatmentAnticoagulant Therapylcsh:Medicine030204 cardiovascular system & hematologyAntiplatelet TherapyPathology and Laboratory MedicineVascular MedicineBrain IschemiaGeographical LocationsElectrocardiography0302 clinical medicineRisk FactorsAtrial FibrillationMedicine and Health SciencesMedicineSinus rhythm030212 general & internal medicinelcsh:ScienceMultidisciplinaryPharmaceuticsIncidence (epidemiology)IncidenceAtrial fibrillationMiddle AgedStrokeCatheterCardiovascular TherapyBioassays and Physiological AnalysisNeurologyCardiologyCatheter AblationFemaleArrhythmiaResearch ArticleBiotechnologymedicine.medical_specialtyCathetersAsiaLong term follow upCerebrovascular DiseasesCardiologyCatheter ablationHemorrhageResearch and Analysis Methods03 medical and health sciencesSigns and SymptomsDrug TherapyDiagnostic MedicineInternal medicineRepublic of KoreaHumansIn patientIschemic StrokeKoreabusiness.industrylcsh:RElectrophysiological TechniquesBiology and Life Sciencesmedicine.diseaseIschemic strokePeople and Placeslcsh:QMedical Devices and EquipmentCardiac ElectrophysiologybusinessFollow-Up StudiesPLoS ONE
researchProduct

Pharmacokinetics of new oral anticoagulants: implications for use in routine care

2018

Introduction: Since 2008, new oral anticoagulants (NOACs) have been approved for the prevention of venous thromboembolism (VTE) in patients receiving hip or knee replacement surgery, prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF), treatment of deep vein thrombosis (DVT), and pulmonary embolism (PE). Premarketing randomized clinical trials (RCTs) of NOACs demonstrated their non-inferiority in terms of efficacy vs. warfarin (traditional oral anticoagulant–TOA), with lower risk of serious adverse drug reactions, especially cerebral hemorrhages. In clinical practice, pharmacokinetic aspects of NOACs have to be carefully taken into account to …

medicine.medical_treatmentnew oral anticoagulantsAdministration OralKnee replacement030204 cardiovascular system & hematologyToxicologyAdherence Bleeding Interactions New oral anticoagulants Over- and under-dosage Persistence Pharmacokinetics Real World Evidence0302 clinical medicineAtrial Fibrillationover- and underdosage030212 general & internal medicinepharmacokineticStrokeRoutine careRandomized Controlled Trials as Topicnew oral anticoagulantAtrial fibrillationpersistenceVenous ThromboembolismGeneral MedicinePulmonary embolismStrokepharmacokineticsHumanmusculoskeletal diseasesmedicine.medical_specialtyinteractionHemorrhageMedication Adherence03 medical and health sciencesPharmacokineticsmedicineHumansReal World EvidenceIn patientOver- and under-dosagecardiovascular diseasesreal-world evidenceIntensive care medicineAgedPharmacologybusiness.industryAnticoagulantAnticoagulantsinteractionsbleedingmedicine.diseaseAdherencePulmonary EmbolismbusinessVenous thromboembolismExpert Opinion on Drug Metabolism &amp; Toxicology
researchProduct

Overcoming a “Probable” Diagnosis in Antimitochondrial Antibody Negative Primary Biliary Cirrhosis: Study of 100 Sera and Review of the Literature

2010

Serum anti-mitochondrial antibodies (AMA) are the serological hallmark of primary biliary cirrhosis (PBC), yet up to 15% of PBC sera are AMA negative at routine indirect immunofluorescence (IIF) while being referred to as “probable” cases. The diagnostic role of PBC-specific antinuclear antibodies (ANA) remains to be determined. We will report herein data on the accuracy of new laboratory tools for AMA and PBC-specific ANA in a large series of PBC sera that were AMA-negative at IIF. We will also provide a discussion of the history and current status of AMA detection methods. We included IIF AMA-negative PBC sera (n = 100) and sera from patients with other chronic liver diseases (n = 104) th…

AdultMaleAnti-nuclear antibodyNuclear dotsPBCSerologyAnticorpo antimitocondrio cirrosi biliare primitivaPrimary biliary cirrhosisAntigenparasitic diseasesHumansImmunology and AllergyMedicineskin and connective tissue diseasesAgedAutoantibodiesAged 80 and overbiologyLiver Cirrhosis Biliarybusiness.industryAutoantibodyIIfGeneral MedicineMiddle Agedmedicine.diseasedigestive system diseasesMitochondriaImmunologybiology.proteinFemaleAntibodybusinessClinical Reviews in Allergy &amp; Immunology
researchProduct

Antiepileptogenic Effect of Subchronic Palmitoylethanolamide Treatment in a Mouse Model of Acute Epilepsy

2018

Research on the antiepileptic effects of (endo-)cannabinoids has remarkably progressed in the years following the discovery of fundamental role of the endocannabinoid (eCB) system in controlling neural excitability. Moreover, an increasing number of well-documented cases of epilepsy patients exhibiting multi-drug resistance report beneficial effects of cannabis use. Pre-clinical and clinical research has increasingly focused on the antiepileptic effectiveness of exogenous administration of cannabinoids and/or pharmacologically induced increase of eCBs such as anandamide (also known as arachidonoylethanolamide [AEA]). Concomitant research has uncovered the contribution of neuroinflammatory p…

0301 basic medicinemedicine.medical_treatmentFAAH inhibitorsPharmacologyeicosanoidslcsh:RC321-57103 medical and health scienceschemistry.chemical_compoundEpilepsyCellular and Molecular Neuroscience0302 clinical medicineFatty acid amide hydrolaseMedicineantiepileptic drugsPentylenetetrazolendocannabinoidsMolecular Biologypalmitoylethanolamidelcsh:Neurosciences. Biological psychiatry. NeuropsychiatryOriginal ResearchPalmitoylethanolamidebusiness.industryAnandamidemedicine.diseaseEndocannabinoid system030104 developmental biologyAnticonvulsantchemistryLC-MRMSystemic administrationlipidomicsepilepsybusiness030217 neurology & neurosurgerymedicine.drugNeuroscienceFrontiers in Molecular Neuroscience
researchProduct